Queen Elizabeth II is the UK’s greatest trade ambassador, and royal approval is a sign of quality and success. These annually bestowed awards praise the most remarkable achievements among British companies in terms of innovation, international trade, sustainable development, and promoting opportunity through social mobility. The first ceremony was held in 1966, and, even today, receiving this award opens a world of opportunities for companies at an international level.
This year 19 British companies from various fields were chosen as winners, including a centre for children with disabilities, a data science company, a company that supports refugees, watercraft manufacturers, a gym equipment supplier, handmade candles producers, a drilling equipment provider and a company that pens that help people with dyslexia, among others. But those who have given the most to talk about have been a sex toy company and a medical cannabis pharmaceutical company.
A Win for Cannabinoid Therapies
Honouring GW Pharmaceuticals, a world-leading company in the development of cannabinoid-based treatments, gives a message of hope for those companies using technology to improve healthcare. Apart from this, GW’s expansion will end the stigma surrounding cannabis products, its use, and benefits.
GW Pharmaceuticals has been carrying out research on cannabinoids since 1998 and achieved world leadership regarding treatments based on plant-derived cannabinoids.
GW’s vision is to be the global leader in prescription cannabinoid medicines, developing and commercializing pharmaceutical products which address clear unmet needs. GW Pharmaceuticals has attained its globally acclaimed reputation in the development of plant-derived cannabinoid therapeutics thanks to its drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
GW has successfully developed the world’s first prescription medicine derived from the cannabis plant, traded as Sativex® in Europe, a formulated cannabis extract that contains the principal cannabinoids delta-9-tetrahydrocannibinol (THC) and cannabidiol (CBD), as well as other minor cannabinoids and terpenes. This medication is now approved in numerous countries outside of the US for the treatment of spasticity due to multiple sclerosis.
GW continues to research and develop cannabis pharmaceutical derivatives and is commencing separate clinical programs in the United States for spasticity caused by multiple sclerosis and spinal cord injury, and for post-traumatic stress disorder (PTSD).
Royal patronage will help companies create more jobs, set up international offices, and progress in medical cannabis use and research.